Brief: Fortress Biotech And Cyprium Therapeutics Announce U.S. FDA Acceptance And Priority Review Of NDA For CUTX-101
06/01/2025 13:48
Jan 6 (Reuters) - Fortress Biotech Inc FBIO.O :
* FORTRESS BIOTECH AND CYPRIUM THERAPEUTICS ANNOUNCE U.S.
FDA
ACCEPTANCE AND PRIORITY REVIEW OF NDA FOR CUTX-101 FOR TREATMENT
OF MENKES DISEASE
* FORTRESS BIOTECH INC - FDA GRANTS PRIORITY REVIEW FOR
CUTX-101,
PDUFA DATE JUNE 30, 2025
Source text: urn:newsml:reuters.com:*:nGNXbtm6Fl
Further company coverage: FBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi